This mechanistic difference may influence efficacy and side effect profiles across different individuals
Food and Drug Administration (FDA) approved Tirzepatide for chronic weight management on November 8, 2023, and the drug was sold under the brand name, Other Options Aside from Semaglutide and Tirzepatide, there are other weight loss injections out there
Compounded versions are only prescribed in compliance with FDA regulations and obtained through licensed pharmacies when appropriate
Incretin analogues also show beneficial effects in heart failure, peripheral vascular disease, renal disease, obstructive sleep apnoea and metabolic dysfunction-associated steatohepatitis and have potential neuroprotective properties
Mumbai: For thousands across the country, this year has brought a sudden relief from a lifetime of struggles with obesity, driven by the arrival of one weight-loss drug in March and then a couple more